|AzPA Pharmacy Flash|
|Aug. 13, 2014|
Save the date: Fall Conference Nov. 15, 2014
Join us at the Kroc Corps Community Center in Phoenix! Participate in the Diabetes Certificate Program or Psychiatric Certificate Program Friday, Nov. 14. AzPA brings you the opportunity to earn up to 6.0 CE credits during our Fall Conference, Saturday, Nov. 15.
Online registration is coming soon. Stay connected on Twitter using #AzpaFall.More
We are pleased to invite you to take part in a web-based educational program!
William Schaffner, MD
The webcast, titled Influenza and Chronic Medical Conditions: How Risk Adds to Risk in the Older Adult, will be moderated by William Schaffner, MD, Professor of Preventive Medicine, Department of Health Policy, and Professor of Medicine, Division of Infectious Diseases at Vanderbilt University School of Medicine in Nashville, Tennessee.
This non-CME presentation will explore ways in which influenza and comorbidities such as heart disease, lung disease and diabetes interact to increase the risks of influenza-related complications, hospitalization and death. The webcast will also stress how important it is for health care providers to identify and immunize patients at high risk of influenza, especially older adults who are likely to have one or more comorbid conditions. Lastly, the program will review why the use of vaccines that generate a higher immune response may be important to help prevent influenza infection and its potentially life-threatening complications in older adults. More
Nominate a colleague for recognition by the American Pharmacists Association!
The APhA Awards and Honors Program is the profession's most comprehensive recognition program. Help us identify the students, practitioners, scientists and organizations most deserving of recognition at the 2015 APhA Annual Meeting & Exposition in San Diego, California. Visit www.pharmacist.com/awards for information. Deadline: Sept. 1.More
2015 APhA Election: Lead. Make Change Happen.
The American Pharmacists Association is seeking leaders to help shape the profession's future. On the Board of Trustees, APhA President-elect and Trustee positions are both available. The available Academy positions are as follows: APhA-APRS Basic Sciences Chair-elect, Clinical Sciences Chair-elect and Economic, Social & Administrative Sciences Chair-elect are open for APhA pharmaceutical scientists and researchers; and APhA-APPM President-elect and Member-at-Large positions are open for APhA pharmacy practitioners. Visit www.pharmacist.com/elections for additional information on available positions. Deadline: Oct. 1.More
FDA authorizes Ebola test; vaccine will probably take until 2015
Los Angeles Times
The FDA has authorized use of an unapproved Ebola virus test under a special emergency-use provision, although efforts to develop a vaccine for the deadly illness are unlikely to bear fruit until 2015, officials say. The test-tube diagnostic test was developed by the U.S. military and is used to detect the Zaire strain of Ebola, which has infected at least 1,711 and killed 932 in West Africa.More
NCPA urges swift congressional action on 'any willing pharmacy' legislation
Key congressional committee leaders were recently encouraged to hold hearings on "any willing pharmacy" legislation by the National Community Pharmacists Association. In letters to the leadership of the House Energy and Commerce Committee and the House Ways and Means Committee, NCPA noted that H.R. 4577, the Ensuring Seniors Access to Local Pharmacies Act, had earned the support of 59 cosponsors, including 12 members of the House Energy and Commerce Committee and once again requested a congressional hearing on preferred networks.More
FDA lifts hold on experimental Ebola drug from Tekmira
The U.S. Food and Drug Administration has eased safety restrictions on an experimental drug to treat Ebola, a move that could clear the way for its use in patients infected with the deadly virus. Canadian drugmaker Tekmira Pharmaceuticals Corp. said the FDA modified a hold recently placed on the company's drug after safety issues emerged in human testing.More
Red flags: Pharmacists anti-abuse video
Pharmacy Practice News
The National Association of Boards of Pharmacy and the Anti-Diversion Industry Working Group, a consortium of pharmaceutical manufacturers and distributors, has created this educational video for pharmacists to help them identify the warning signs of prescription drug abuse and diversion when dispensing controlled substance prescriptions.More
Diabetes intervention spearheaded by pharmacist improves glycemic control
A pharmacist-led intense disease management clinic successfully aided patients with type 2 diabetes mellitus and their primary care providers in achieving improved glycemic control, according to study results presented at the 74th Scientific Sessions of the American Diabetes Association. More
University of Kentucky pharmacy professor develops nasal spray to stop heroin overdoses
A University of Kentucky pharmacy professor has developed a nasal spray to stop heroin and other opioid overdoses, and his invention has now been fast-tracked by the Food and Drug Administration.More
Olodaterol approved for COPD
FDA and Boehringer Ingelheim announced the approval of olodaterol oral inhalation spray as a long-term, once-daily maintenance bronchodilator to relieve airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.More
Stop whining: Insurers and the high price hype of Hepatitis C
By Jason Poquette
There has been a lot of fuss in the media over the price of the newest treatment options for Hepatitis C, a condition affecting around 3 million Americans.More
False hope for new superbug treatments
By Mike Wokasch
The lack of effective treatments for antibiotic-resistant "superbugs" represents a serious global healthcare issue with potentially disastrous consequences. In the hopes of finding new treatments, a number of organizations and governments are struggling to secure and provide sufficient financial and nonfinancial incentives to encourage more research. Unfortunately, the fallacy of some of these initiatives is that more money, more companies and more compounds will not deliver the products we need.More
FDA approves Orbactiv to treat skin infections
U.S. Food and Drug Administration
The U.S. Food and Drug Administration recently approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections. Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), various Streptococcus species and Enterococcus faecalis.More
North Carolina scientists research chikungunya vaccine
A new vaccine is on its way to stop the spread of a mosquito-borne virus that just made its way to the U.S., and the research is happening in the Carolinas. FOX Carolina traveled to Raleigh for an exclusive look inside the lab that's trying to stop the spread of chikungunya.More